EPISODE · Feb 2, 2026 · 2 MIN
Comparing 225Ac-PSMA-617 and 177Lu-PSMA-617 in Prostate Cancer
from TheBrief.Health · host TheBrief.Health
ANDROMEDA trial compares alpha and beta PSMA radioligand therapies with SBRT for recurrent oligometastatic prostate cancer, aiming to improve disease control and quality of life.
What this episode covers
ANDROMEDA trial compares alpha and beta PSMA radioligand therapies with SBRT for recurrent oligometastatic prostate cancer, aiming to improve disease control and quality of life.
NOW PLAYING
Comparing 225Ac-PSMA-617 and 177Lu-PSMA-617 in Prostate Cancer
No transcript for this episode yet
Similar Episodes
Apr 21, 2026 ·13m
Apr 19, 2026 ·16m
Apr 17, 2026 ·13m
Apr 13, 2026 ·11m
Apr 11, 2026 ·16m